crsp

At first, I thought maybe the company had released new clinical data, or Lonvo-z had made some progress. But after looking through it, I didn’t find anything particularly important that NTLA suddenly announced.
So this round of上涨, I tend to see it more as a sector rebound, not as the company’s fundamentals suddenly improving.
Today, these gene-editing stocks are basically all up, $CRSP.US and $BEAM.US are both close to 10%, $EDIT.US is also up by around 7%, and the $XBI is strengthening too. When everyone is rising together, usually you can’t attribute the reason to just one company.